Evidence map›Paper›PMID 33552256›Full record

ArticleOncology letters2021

MicroRNA-200a and microRNA-141 have a synergetic effect on the suppression of epithelial-mesenchymal transition in liver cancer by targeting STAT4.

Shuying Chen, Jingjun Zhang, Qiudan Chen, Juan Cheng, Xiaotong Chen, Yinqi Mao, Wei Chen, Chenbin Liu, Han Wu, Yuan Lv and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Shuying ChenDepartment of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Jingjun ZhangDepartment of Rehabilitation, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Qiudan ChenDepartment of Central Laboratory, Clinical Laboratory, Jingan District Central Hospital, Fudan University, Shanghai 200040, P.R. China.
Juan ChengDepartment of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China.
Xiaotong ChenDepartment of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Yinqi MaoSchool of Medicine, Shanghai Jiao Tong University, Shanghai 200025, P.R. China.
Wei ChenSchool of Medicine, Shanghai Jiao Tong University, Shanghai 200025, P.R. China.
Chenbin LiuSchool of Medicine, Shanghai Jiao Tong University, Shanghai 200025, P.R. China.
Han WuSchool of Medicine, Shanghai Jiao Tong University, Shanghai 200025, P.R. China.
Yuan LvDepartment of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Yong LinDepartment of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Huashan Hospital · CNShanghai Jiao Tong University · CNFudan University · CNAnhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs or miRs) are non-coding small RNAs that target specific messenger RNAs to inhibit protein translation. miR-200a and miR-141 function as tumor suppressors by targeting STAT4. These two miRNAs belong to the same family, and their expression is often decreased in various cancer types, but are located on different chromosomes of the human genome. The present study showed that the expression levels of miR-141 and miR-200a in serum and cells of liver cancer are significantly downregulated. The expression levels of miR-141 and miR-200a are closely associated with clinicopathological features of liver cancer, especially metastasis and invasion. It is first reported that STAT4 is the new common target gene of miR-141 and miR-200a. In the present study, miR-141 and miR-200a were confirmed to inhibit the expression of E-cadherin and vimentin synergistically during epithelial-mesenchymal transition to regulate the proliferation, migration and invasion of liver cancer cells by targeting STAT4. Simultaneous overexpression of miR-200a and miR-141 resulted in stronger effects compared with each miRNA alone. In addition, overexpression of STAT4 significantly reversed the tumor suppressive roles of miR-200a and miR-141 in liver cancer cells. These findings enrich the tumor suppressor mechanisms of the miR-200 family, and may also provide new experimental and theoretical basis for the use of miRNAs for early diagnosis, prognosis and thorough treatment of liver cancer.

Indexed as

liver cancermicroRNA-141microRNA-200aSTAT4

Identifiers

PMID33552256
PMCPMC7798046
OpenAlexW3116003011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.